RecruitingRetinopathyRetinal Vein OcclusionDiabetic Retinopathy
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
Sponsor: MediBeacon
You may qualify if…
- ✓ Age \> 18 years - male or female
- ✓ 1. Eligible female non-pregnant participants who are either not of child-bearing potential or willing to utilize adequate contraception during the trial
- ✓ 2. Males must be willing to practice abstinence or utilize adequate contraception from MB-102 dosing day to at least 7 days post dose
- ✓ Participants willing to comply with study requirements
- ✓ Participants who have signed an informed consent form
- ✓ At least 5 participants will have a current history of retinal or choroidal vascular diseases.
You may not qualify if…
- ✕ Women who are pregnant, lactating or planning to become pregnant during the study, or women who are of childbearing potential unwilling to utilize adequate contraception
- ✕ Participation in another interventional trial within 30 days of treatment or concurrently enrolled in any other medical research study which could impact the results of the study
- ✕ History of drug or alcohol abuse within the past year
- ✕ History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 and fluorescein sodium or other related products (intolerance to a drug is not considered a drug allergy).
- ✕ Prior history of seizures
- ✕ Current visually significant cataracts or other ophthalmic conditions that would limit appropriate collection of fundus photographs
- ✕ Site personnel immediately associated with the study or their immediate family members
- ✕ Unable to tolerate ophthalmologic imaging
Where it's recruiting
Michigan
Ann Arbor
Source: ClinicalTrials.gov · NCT04008121 · last updated 2026-02-04